Defibrotide Euglobulin Assay for Reproducible Activity Measurement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for determining the biological activity of defibrotide are not precise, reproducible, and do not accurately reflect its mechanism of action in a complex biological system, leading to variability in medicinal preparations.
Innovation Solution
An indirect enzymatic method using euglobulin and a plasmin-specific substrate to measure the rate of compound release, which correlates with defibrotide concentration, allowing for precise and accurate determination of biological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If classical extraction and purification processes are used to obtain defibrotide, then the product can be characterized by physico-chemical parameters, but the biological activity cannot be accurately determined due to batch variability inherent in natural biopolymers
Solution Approach 1:
The patent changes the measurement parameter from physico-chemical characteristics (molecular weight, electrophoretic mobility) to a functional biological parameter (fibrinolytic activity). This allows direct measurement of defibrotide's biological effect rather than relying on physical properties that vary between batches, thereby resolving the contradiction between measurement precision and compositional stability.
Solution Approach 2:
The patent replaces mechanical/physical measurement methods with a biological assay system. Instead of measuring physical properties that are inherently variable in natural biopolymers, the invention uses a biological response (fibrin lysis) to quantify defibrotide activity, substituting physical measurement with biological measurement to achieve better precision.
2Measurement precision
If existing methods such as fibrin plate test or thromboelastographic recording are used, then biological activity can be evaluated, but the methods are characterized by considerable experimental complexity and unsatisfactory reproducibility
Solution Approach 1:
The patent extracts and isolates the essential functional interaction between defibrotide and fibrin, removing unnecessary complex components from the assay system. By using a simplified in vitro model that focuses solely on the fibrinolytic mechanism, the invention reduces experimental complexity while maintaining measurement precision.
Solution Approach 2:
The patent introduces plasmin as an intermediary enzyme in the assay system. Defibrotide activates plasminogen to plasmin, which then degrades fibrin. This intermediary mechanism provides a measurable and reproducible readout that simplifies the overall experimental design compared to direct fibrin plate tests or thromboelastography.
3Manufacturing precision
If physico-chemical parameters are determined to characterize defibrotide, then production standards can be set, but these parameters do not provide information on biological activity
Solution Approach 1:
The patent performs preliminary characterization of defibrotide batches using the fibrinolytic assay before final product release. This preliminary biological activity testing ensures that each batch meets the required functional standards, providing both manufacturing precision and biological activity information simultaneously.
Solution Approach 2:
The patent creates a multi-functional characterization system that simultaneously determines both physico-chemical parameters (for manufacturing control) and biological activity (for functional performance). The fibrinolytic assay serves as a universal test that provides both production standard verification and biological efficacy data, eliminating the loss of biological activity information.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides high precision and accuracy in determining defibrotide activity, enabling standardized medicinal preparations by correlating the rate of plasminogen hydrolysis to defibrotide concentration, even in the presence of contaminants.
Implementation Method 1
defibrotide catalyzes the hydrolysis of plasminogen contained in euglobulin into plasmin
Implementation Method 2
defibrotide catalyzes the hydrolysis of plasminogen contained in euglobulin into plasmin; which plasmin enzymatically reacts with the substrate specific for plasmin
Data Source
AI summary
It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU/mg of defibrotide, preferably from 27 to 32 IU/mg and, more preferably, from 28 to 32 IU/mg.